The purpose of this trial is to determine if genex with gentamicin (genex G) an antibiotic loaded bone void filler, works to treat and is a safe option as part of the surgical treatment of osteomyelitis in the extremities.
This trial is a multi-center, single arm, historically controlled, pivotal device study. All participants diagnosed with osteomyelitis of the extremities (Cierny-Mader Classification grades I-IV) can be considered. All participants will undergo surgical debridement and will receive genex with gentamicin (genex G) antibiotic loaded bone void filler as part of the surgical treatment of osteomyelitis of the extremities. Participants will receive antibiotics per site specific requirements as clinically indicated. All participants will be followed up for 24 Months.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
139
genex with gentamicin will be implanted during debridement surgery
North Park Podiatry
San Diego, California, United States
RECRUITINGOrthoIndy
Indianapolis, Indiana, United States
RECRUITINGSinai Hospital Baltimore
Baltimore, Maryland, United States
RECRUITINGNo further requirement for antibiotic treatment due to persisting symptoms of infection at the index site (i.e., additional antibiotics prescribed following completion of the initial systemic antibiotics prescribed post surgery.
Further requirement for antibiotic treatment due to persisting symptoms of infection at the site of treatment will be assessed at Month 12.
Time frame: Month 12
No further surgical interventions required due to infection at the index site.
Need for further surgical interventions required due to infection at the index site will be assessed at Month 12.
Time frame: Month 12
No recurrence of sinus formation at the index site.
Recurrence of sinus formation at the index site will be assessed by a non-contrast CT scan at week 2 \& Month 12. Clinical endpoint assessments will also be used to measure this at post operative follow-up visits and will be assessed at Month 12.
Time frame: Month 12
No additional requirement for antibiotic treatment due to persisting symptoms of infection at the treatment site, i.e., additional antibiotics prescribed following completion of the initial systemic antibiotics prescribed post-surgery.
Further requirement for antibiotic treatment due to persisting symptoms of infection at the site of treatment will be assessed at Month 24.
Time frame: Month 24
No radiographic evidence of post op fractures.
Radiographic evidence of post-operative fractures will be evidenced by X-ray \& CT evaluations and assessed at Month 24.
Time frame: Month 24
Radiographic evidence of new bone healing.
Radiographic evidence of new bone healing will be evidenced by X-ray and CT evaluations and assessed at Month 24.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Curalta Clinical Trials
Oradell, New Jersey, United States
RECRUITINGTime frame: Month 24
No recurrence of sinus formation at the treatment site.
Recurrence of sinus formation at the index site will be assessed by contrast enhanced CT evaluation and Clinical endpoint assessments measured at Month 24.
Time frame: Month 24
No secondary surgical interventions (SSI's) related to the investigational treatment.
Secondary Surgical interventions (SSI's) related to the investigational treatment will be assessed at Month 24.
Time frame: Month 24
No serious adverse events that are definitely related to genex G.
Serious adverse events that are definitely related to genex G will be assessed at Month 24.
Time frame: Month 24
Radiographic Evidence of new bone formation and product reabsorption.
Radiographic evidence of new bone formation and product reabsorption will be evidenced by X-ray and CT evaluations during the course of the trial and recorded on the participants electronic case report form (eCRF).
Time frame: Month 24
Infection resolution evaluated by radiographic assessment and clinical endpoints.
Radiographic evidence of infection resolution will be evidenced by contrast enhanced CT evaluations and clinical endpoint assessments assessed during the course of the trial and recorded on the participants electronic case report form (eCRF).
Time frame: Month 24
Adverse events including wound problems, reaction to combination product, fracture at treatment site.
Adverse events including wound problems, reaction to combination product, fracture at treatment site will be assessed during the course of the trial and recorded on the participants electronic case report form (eCRF).
Time frame: Month 24
Secondary Surgical Interventions (SSI's)
Number of Secondary Surgical Interventions (SSI's) will be assessed during the course of the trial and recorded on the participants electronic case report form (eCRF).
Time frame: Month 24
Number of participants discontinuing therapy prematurely due to a device related event.
Number of participants discontinuing therapy prematurely due to a device related event will be assessed during the course of the trial and recorded on the participants electronic case report form (eCRF).
Time frame: Month 24
Number of hospitalisations/re-hospitalisation due to treatment site Osteomyelitis.
Number of hospitalisations/re-hospitalisation due to treatment site Osteomyelitis.
Time frame: Month 24
Quality of Life EQ-5D-5L
Impact on the participants Quality of Life will be measured by the EQ-5D-5L during the course of the trial and recorded on the participants electronic case report form (eCRF).
Time frame: Month 24